{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:50:34Z","timestamp":1783957834996,"version":"3.55.0"},"reference-count":39,"publisher":"Guttmacher Institute","issue":"2","license":[{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Perspect Sexual Reproductive"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Context<\/jats:title><jats:p>Removing the prescription requirement and making oral contraceptive pills available over the counter (OTC) could increase contraceptive access in the United States. Despite current efforts to make a progestin\u2010only pill (POP) available OTC, there are no qualitative data exploring the experiences of POP users and their perspectives on making POPs available OTC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted six online, asynchronous focus group discussions with 36 POP users between July and November 2020. We stratified focus group discussion placement based on three reasons for POP use: breastfeeding, having a contraindication to estrogen (for a reason other than breastfeeding), and for any other reason. We thematically analyzed these data using inductive and deductive coding.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The majority of participants described their overall POP experience as positive, mostly because they experienced minor or no side effects and thought the pill was effective. Participants overwhelmingly supported OTC availability of POPs and expressed interest in purchasing an OTC POP. Over one\u2010third of participants had very limited knowledge or held inaccurate assumptions about POPs before they started using this method and many stressed the need to disseminate accurate information and resources about POPs to the public.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Most focus group discussion participants were satisfied with POPs and supported OTC access. While misconceptions and concerns about POPs should be addressed, an OTC POP has the potential to be a safe, effective, and convenient contraceptive option in the United States.<\/jats:p><\/jats:sec>","DOI":"10.1363\/psrh.12223","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T07:34:55Z","timestamp":1681198495000},"page":"104-112","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Experiences of progestin\u2010only pill users in the United States and attitudes toward over\u2010the\u2010counter access"],"prefix":"10.1363","volume":"55","author":[{"given":"Carmela","family":"Zuniga","sequence":"first","affiliation":[{"name":"Ibis Reproductive Health  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Forsberg","sequence":"additional","affiliation":[{"name":"Ibis Reproductive Health  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Grindlay","sequence":"additional","affiliation":[{"name":"Ibis Reproductive Health  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"259","published-online":{"date-parts":[[2023,4,11]]},"reference":[{"key":"e_1_2_6_2_1","article-title":"Current contraceptive status among women aged 15\u201349: United States, 2017\u20132019","author":"Daniels K","year":"2020","journal-title":"NCHS Data Brief No 388"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2006.07.006"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2015.5312"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1363\/3904807"},{"key":"e_1_2_6_6_1","unstructured":"Guttmacher Institute.Pharmacist\u2010prescribed contraceptives. Guttmacher Institute.2020Accessed July 29 2021.https:\/\/www.guttmacher.org\/state-policy\/explore\/pharmacist-prescribed-contraceptives"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2016.05.003"},{"key":"e_1_2_6_8_1","unstructured":"KritzF.Pharmacists can now prescribe birth control but few do. California Health Report 2019.2019Accessed July 29 2021.https:\/\/www.calhealthreport.org\/2019\/02\/15\/pharmacists-can-now-prescribe-birth-control-but-few-do-%ef%bb%bf\/"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2019.05.013"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2012.11.021"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31818345f0"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2012.01.008"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2021.01.010"},{"key":"e_1_2_6_14_1","unstructured":"American Medical Association.Over\u2010the\u2010counter contraceptive drug access (Resolution 110\u2010A\u201017).2018Accessed July 29 2021.https:\/\/ocsotc.org\/wp-content\/uploads\/2018\/06\/2018-AMA-OCs-OTC-resolution-110-A-17.pdf"},{"issue":"4","key":"e_1_2_6_15_1","first-page":"10","article-title":"Over\u2010the\u2010counter access to hormonal contraception","volume":"134","author":"American College of Obstetricians and Gynecologists","year":"2019","journal-title":"Obstet Gynecol"},{"key":"e_1_2_6_16_1","unstructured":"American Academy of Family Physicians.Over\u2010the\u2010counter oral contraceptives.2021Accessed July 29 2021.https:\/\/www.aafp.org\/about\/policies\/all\/otc-oral-contraceptives.html"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1603"},{"key":"e_1_2_6_18_1","unstructured":"HRA Pharma (last).Perrigo's HRA Pharma submits application to FDA for first\u2010ever OTC birth control pill. HRA_Pharma. Accessed October 18 2022.https:\/\/www.hra-pharma.com\/articles\/perrigos-hra-pharma-submits-application-to-fda-for-first-ever-otc-birth-control-pill-66"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2012.05.018"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2012.05.003"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.whi.2017.11.006"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjsrh\u20102022\u2010201637"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1089\/whr.2022.0056"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2020.1821649"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2016.12.008"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/13625189809167250"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5659.730"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010\u20107824(74)90012\u20102"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010\u20107824(90)90077\u20109"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2015.07.014"},{"key":"e_1_2_6_31_1","volume-title":"Advances in Planned Parenthood: Proceedings of the 9th Annual Meeting of the American Association of Planned Parenthood Physicians, Kansas City, Mo","author":"McQuarrie HG","year":"1972"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007611\u2010197601000\u201000017"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(71)90624-7"},{"key":"e_1_2_6_34_1","first-page":"295","article-title":"Low dosage progestagen as an oral contraceptive: a clinical study","volume":"109","author":"Whyte JC","year":"1973","journal-title":"Can Med Assoc J"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2004.07.016"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2015.12.007"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2016.12.024"},{"key":"e_1_2_6_38_1","article-title":"Mean age of mothers is on the rise: United States, 2000\u20132014","author":"Mathews TJ","year":"2016","journal-title":"NCHS Data Brief No 232"},{"key":"e_1_2_6_39_1","article-title":"Current contraceptive status among women aged 15\u201349: United States, 2015\u20132017","author":"Daniels K","year":"2018","journal-title":"NCHS Data Brief No. 237"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/1609406917733847"}],"container-title":["Perspectives on Sexual and Reproductive Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1363\/psrh.12223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T16:20:56Z","timestamp":1692548456000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1363\/psrh.12223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1363\/psrh.12223"],"URL":"https:\/\/doi.org\/10.1363\/psrh.12223","archive":["Portico"],"relation":{},"ISSN":["1538-6341","1931-2393"],"issn-type":[{"value":"1538-6341","type":"print"},{"value":"1931-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,11]]},"assertion":[{"value":"2023-04-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}